SCB 102
Alternative Names: SCB-102Latest Information Update: 01 Sep 2022
At a glance
- Originator SciBac
- Class Bacteria; Gene therapies
- Mechanism of Action Bacteria replacements; Bacterial toxin inhibitors; Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Clostridium difficile infections
Most Recent Events
- 01 Sep 2022 Discontinued - Early research for Clostridium difficile infections (Prevention) in USA (PO), prior to August 2022 (Scibac pipeline, August 2022)
- 01 Sep 2022 Discontinued - Early research for Clostridium difficile infections in USA (PO), (Scibac pipeline, August 2022)
- 26 Aug 2022 No development reported - Early research for Clostridium difficile infections in USA (PO)